Marie-Dominique Mompas is the founder of Viglya. She studied Pharmaceutical Science at the Université Paris-Sud in France and she holds both a doctorate degree in Pharmacy (PharmD) and a Master’s Degree in international law from the same university. She has worked for more than 18 years in the pharmaceutical industry in both large and small pharmaceutical and biotechnology companies, at different levels of responsibility, in regulatory affairs and pharmacovigilance. This experience has resulted in her extensive knowledge and profound understanding of the international regulatory landscape.
Furthermore, she spent 12 years working in the United States for such multinational companies as Bristol-Myers Squibb and Pfizer, and at biotechnology companies such as Agouron Pharmaceuticals. Her last position in the United States was as Director of Regulatory Strategy at Pfizer where she dealt directly with the FDA for the conduct of clinical programs, the preparation and negotiation of regulatory submissions (CDER), and the management of advertising and promotional activities (DDMAC) for HIV products.
Most recently, she worked as Head of Corporate Drug Safety and European Qualified Person for Pharmacovigilance at Almirall in Spain, for 6 years, where she developed their pharmacovigilance system, with particular focus on the safety monitoring of investigational drugs and safety signal detection activities for marketed products.